The company states: "Consistent with the guidance issued by Integra LifeSciences on January 10, 2023, the Company’s adjusted earnings per diluted share results, which is a non-GAAP financial measure, for the fourth quarter and full-year 2022 are expected to be above the high end of the Company’s October guidance range. Q4 adjusted earnings per diluted share is expected to be in a range of $0.92 to $0.96 compared to $0.84 in 2021. FY22 adjusted earnings per diluted share is expected to be in a range of $3.34 to $3.38 compared to $3.18 in 2021." FY22 EPS consensus is $3.30.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IART:
- Campbell Soup names Carrie Anderson as new CFO
- Integra LifeSciences Reports Select Preliminary Fourth Quarter and Full-Year 2022 Financials
- Integra LifeSciences reiterates plans to initiate $150M share buyback in 2023
- Integra sees FY22 adjusted EPS above $3.29-$3.33 range, consensus $3.30
- Integra LifeSciences sees Q4 revenue $397M-$398M, consensus $397.5M